Table 2.
Potential beneficial targeted medicine for patients.
| Mutations | FDA approved for this cancer | FDA approved for other cancers | Phase II/III clinical trials |
|---|---|---|---|
| CDKN2A | Palbociclib, Ribociclib | Defactinib | |
| PIK3CA | Everolimus、Temsirolimus | Ipatasertib, GDC-0077 | |
| PTEN | Alpelisib, Copanlisib | Ipatasertib, GSK2636771 | |
| TSC1, TSC2 | Everolimus, Temsirolimus | Sapanisertib, LY3023414 | |
| BRAF | Encorafenib+Binimetinib | Ulixertinib, PLX8394 | |
| BRCA2 | Rucaparib, Talazoparib | ||
| KRAS | Cobimetinib, Binimetinib | ||
| NF1 | Temsirolimus, Cobimetinib | ||
| IDH1 | Ivosidenib | ||
| PTCH1 | Vismodegi, Sonidegib |
FDA, food and durg administration. Currently, very limited medicine has been approved for treating glioma. This will be improved with the development of precision medicine.